🎉 M&A multiples are live!
Check it out!

Alembic Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Alembic Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Alembic Pharmaceuticals Overview

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Founded

2010

HQ

India
Employees

14.9K+

Financials

LTM Revenue $761M

LTM EBITDA $121M

EV

$2.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals has a last 12-month revenue of $761M and a last 12-month EBITDA of $121M.

In the most recent fiscal year, Alembic Pharmaceuticals achieved revenue of $710M and an EBITDA of $112M.

Alembic Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Alembic Pharmaceuticals valuation multiples based on analyst estimates

Alembic Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $639M $710M XXX XXX XXX
Gross Profit $408M $404M XXX XXX XXX
Gross Margin 64% 57% XXX XXX XXX
EBITDA $79.0M $112M XXX XXX XXX
EBITDA Margin 12% 16% XXX XXX XXX
Net Profit $60.5M $39.7M XXX XXX XXX
Net Margin 9% 6% XXX XXX XXX
Net Debt $66.1M $65.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Alembic Pharmaceuticals Stock Performance

As of April 15, 2025, Alembic Pharmaceuticals's stock price is INR 847 (or $10).

Alembic Pharmaceuticals has current market cap of INR 167B (or $1.9B), and EV of INR 176B (or $2.0B).

See Alembic Pharmaceuticals trading valuation data

Alembic Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.0B $1.9B XXX XXX XXX XXX $0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Alembic Pharmaceuticals Valuation Multiples

As of April 15, 2025, Alembic Pharmaceuticals has market cap of $1.9B and EV of $2.0B.

Alembic Pharmaceuticals's trades at 2.7x LTM EV/Revenue multiple, and 16.8x LTM EBITDA.

Analysts estimate Alembic Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Alembic Pharmaceuticals and 10K+ public comps

Alembic Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.0B XXX XXX XXX
EV/Revenue 2.7x XXX XXX XXX
EV/EBITDA 17.3x XXX XXX XXX
P/E 28.5x XXX XXX XXX
P/E/Growth 1.3x XXX XXX XXX
EV/FCF 47.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Alembic Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Alembic Pharmaceuticals Valuation Multiples

Alembic Pharmaceuticals's NTM/LTM revenue growth is 11%

Alembic Pharmaceuticals's revenue per employee for the last fiscal year averaged $48K, while opex per employee averaged $27K for the same period.

Over next 12 months, Alembic Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Alembic Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Alembic Pharmaceuticals and other 10K+ public comps

Alembic Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 11% XXX XXX XXX XXX
EBITDA Margin 16% XXX XXX XXX XXX
EBITDA Growth 41% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 27% XXX XXX XXX XXX
Revenue per Employee $48K XXX XXX XXX XXX
Opex per Employee $27K XXX XXX XXX XXX
S&M Expenses to Revenue 16% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue 0% XXX XXX XXX XXX
Opex to Revenue 56% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Alembic Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Alembic Pharmaceuticals M&A and Investment Activity

Alembic Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Alembic Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Alembic Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Alembic Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Alembic Pharmaceuticals

When was Alembic Pharmaceuticals founded? Alembic Pharmaceuticals was founded in 2010.
Where is Alembic Pharmaceuticals headquartered? Alembic Pharmaceuticals is headquartered in India.
How many employees does Alembic Pharmaceuticals have? As of today, Alembic Pharmaceuticals has 14.9K+ employees.
Who is the CEO of Alembic Pharmaceuticals? Alembic Pharmaceuticals's CEO is Mr. Chirayu R. Amin.
Is Alembic Pharmaceuticals publicy listed? Yes, Alembic Pharmaceuticals is a public company listed on BOM.
What is the stock symbol of Alembic Pharmaceuticals? Alembic Pharmaceuticals trades under 533573 ticker.
When did Alembic Pharmaceuticals go public? Alembic Pharmaceuticals went public in 2011.
Who are competitors of Alembic Pharmaceuticals? Similar companies to Alembic Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Alembic Pharmaceuticals? Alembic Pharmaceuticals's current market cap is $1.9B
What is the current revenue of Alembic Pharmaceuticals? Alembic Pharmaceuticals's last 12-month revenue is $761M.
What is the current EBITDA of Alembic Pharmaceuticals? Alembic Pharmaceuticals's last 12-month EBITDA is $121M.
What is the current EV/Revenue multiple of Alembic Pharmaceuticals? Current revenue multiple of Alembic Pharmaceuticals is 2.7x.
What is the current EV/EBITDA multiple of Alembic Pharmaceuticals? Current EBITDA multiple of Alembic Pharmaceuticals is 16.8x.
What is the current revenue growth of Alembic Pharmaceuticals? Alembic Pharmaceuticals revenue growth between 2023 and 2024 was 11%.
Is Alembic Pharmaceuticals profitable? Yes, Alembic Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.